Impact of Robotic Surgery on Oncologic Treatment: Literature Review

Robotic surgery has become one of the most promising innovations in surgical oncology, providing magnified three-dimensional visualization, seven-degree-of-freedom articulated instrumentation, and physiologic tremor elimination, which together enable more delicate dissections in restricted anatomical fields. Randomized trials and cohort series report lower intra-operative blood loss, shorter hospital stays, and faster functional recovery when compared with conventional laparoscopy and open surgery. Robotic technology has also enabled more extensive lymphadenectomies and preservation of critical neurovascular structures, resulting in better postoperative quality of life, particularly for pelvic and mediastinal tumors. Nevertheless, evidence of oncologic superiority in terms of overall survival and recurrence remains inconsistent, requiring long-term follow-up and robust multicenter trials. Major barriers to wider adoption include the system’s initial cost, expensive maintenance, and the need for formal training with a prolonged learning curve factors that restrict access to economically advantaged centers of excellence. Finally, artificial intelligence, augmented reality, and high-latency teleoperation are emerging trends that could democratize robotics and mitigate current limitations. In conclusion, despite substantial proven advances, equitable adoption of robotic platforms will depend on cost reductions, expansion of training programs, and production of long-term oncologic effectiveness data.